Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 17, 2026Molecular Genetics and Metabolism ReportsOpen Access

Impact of migalastat therapy on corneal deposits in a female with Fabry disease: A case report

View Full Paper
Ask AI
Bookmark
Share

Authors

NVNicola VitturiGGGiorgia GugelmoFZFrancesca Zanini

Discussion

Loading...

Member takes

Overview

Case report examines migalastat's impact on corneal deposits in a female with Fabry disease, indicating treatment significance.

Key Points

  • This report investigates the impact of migalastat therapy on corneal deposits in a female with Fabry disease, particularly during therapy interruptions.
  • Monitored corneal deposits before and after migalastat therapy in a female patient.
  • Considered effects during therapy interruptions due to pregnancies.
  • Conducted multidisciplinary evaluations including ophthalmologic follow-up.
  • Migalastat therapy showed a reduction in corneal deposits over time.
  • Therapy interruptions correlated with periods of increased deposit formation.
  • Ongoing monitoring emphasized the importance of continuous treatment for disease management.

Cite This Study

Vitturi et al. (2026) studied this question.

synapsesocial.com/papers/6a095c3f7880e6d24efe2567https://doi.org/10.1016/j.ymgmr.2026.101318
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Long-term efficacy of migalastat in females with Fabry disease2025 · 2 citations
  2. 2Impact of enzyme replacement therapy and migalastat on disease progression in females with fabry disease2025
  3. 3Safety and efficacy of migalastat in Fabry's disease treatment with cardiac impact : a systematic review and meta-analysis2025
  4. 4Gastrointestinal involvement in fabry disease2024 · 3 citations
  5. 5Renal and multisystem effectiveness of 3.9 years of migalastat in a global real‐world cohort: Results from the <scp>followME</scp> Fabry <scp>Pathfinders</scp> registry2024 · 19 citations